Support is requested to permit continued participation in the cooperative clinical trials of the Southeastern Cancer Study Group which is dedicated to improving the treatment of cancer. UAB will participate in: Phase I studies of toxicity of new drugs, new schedules of dosage or new combinations of drugs and other modalities; Phase II non-randomized studies using historical controls of randomized studies using concurrent population controls, of the effectiveness of a specific treatment in a series of patients with specific cancers; Phase III randomized comparisons of two or more treatment plans. Emphasis is placed on multi-modality programs and adjuvant treatment programs. The above studies are directed against adult cancers, including leukemias, lymphomas, breast cancer, lung cancer, gastrointestinal cancers, malignant melanoma and other solid tumors. The various modalities being developed and tested include surgery, radiotherapy, drugs and biologic response modifiers. Pathology review will be stressed. In addition to Group studies as described, ancillary studies are encouraged. Thorough planning, careful review of data, and statistically sound evaluation of results are essential components. Important secondary benefits of these studies are the excellence of patient care and improved training of medical students and house officers which ensue.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA003013-29
Application #
3555719
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1977-08-01
Project End
1987-07-31
Budget Start
1985-08-01
Budget End
1987-07-31
Support Year
29
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
Schools of Medicine
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Power, Carl A; Pwint, Hnin; Chan, Jeffrey et al. (2009) A novel model of bone-metastatic prostate cancer in immunocompetent mice. Prostate 69:1613-23
Volger, W R; Weiner, R S; Moore, J O et al. (1995) Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial). Leukemia 9:1456-60
Omura, G A; Bass, D (1994) Prognostic factor analysis of central nervous system relapse in adult acute lymphoblastic leukemia. A Southeastern Cancer Study Group report. Am J Clin Oncol 17:93-6
Omura, G A; Vogler, W R; Martelo, O et al. (1994) Late intensification therapy in adult acute lymphoid leukemia: long-term follow-up of the Southeastern Cancer Study Group experience. Leuk Lymphoma 15:71-8
Vogler, W R; McCarley, D L; Stagg, M et al. (1994) A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial. Leukemia 8:1847-53
Johnson, D H; Bass, D; Einhorn, L H et al. (1993) Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. J Clin Oncol 11:1223-9
Martelo, O J; Omura, G A; Gordon, D S et al. (1992) Late intensification therapy in adult acute lymphoid leukemia. The Southeastern Cancer Study Group Experience. Am J Clin Oncol 15:61-8
Vogler, W R; Velez-Garcia, E; Weiner, R S et al. (1992) A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol 10:1103-11
Vogler, W R; Raney, M R (1988) Prognostic significance of blood and marrow findings in acute myelogenous leukemia in remission. A Southeastern Cancer Study Group report. Cancer 61:2481-6
Itoh, K; Balch, C M; Trial, J et al. (1988) CD8+ T cells lyse autologous monocytes in the presence of anti-CD3 monoclonal antibody: association with interleukin-1 production. Cell Immunol 114:257-71

Showing the most recent 10 out of 52 publications